Drug intelligence / Profile preview

lactobacillus acidophilus FB0012 + lactobacillus plantarum FB0015 + lactobacillus rhamnosus FB0047

Development stage: Unknown
Lead developer: FitBiomics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Nella is a probiotic dietary supplement developed by Fitbiomics, a biotechnology company spun out from Harvard University's Wyss Institute. The formulation consists of three specific bacterial strains—Lactobacillus acidophilus FB0012, Lactobacillus plantarum FB0015, and Lactobacillus rhamnosus FB0047—which were originally isolated from the microbiomes of elite athletes. The product is designed to optimize the gut microbiome to support physical performance and recovery, specifically targeting improvements in sleep quality, energy levels, and bowel regularity. Clinical data suggests that supplementation leads to significant improvements in these areas within two weeks, including a reported 37% increase in bowel regularity compared to placebo.

Other names: Nella probioticathlete-derived probiotics

Beyond the preview

Go deeper on lactobacillus acidophilus FB0012 + lactobacillus plantarum FB0015 + lactobacillus rhamnosus FB0047.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus acidophilus FB0012 + lactobacillus plantarum FB0015 + lactobacillus rhamnosus FB0047.

Explore the full profile